Loading stock data…
Exelixis (EXEL)
$54.28-0.49 (-0.89%)
Market ClosedLast close Jun 29
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Exelixis, Inc. in the Healthcare sector is trading at $54.28 with a market capitalization of $13.3B. Wall Street consensus targets $49.50 (16 analysts), implying a -8.8% move over the next 12 months. The stock is currently near its 52-week high of $55.91, remaining 23.5% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply -8.8% downside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $610.81M↑ | $598.66M↑ | $597.75M↑ | $568.26M↑ | $555.45M |
| Gross Profit | $590.86M↑ | $572.18M↓ | $579.18M↑ | $548.79M↑ | $536.27M |
| Operating Income | $251.34M↑ | $235.91M↓ | $256.36M↑ | $213.58M↑ | $186.86M |
| Net Income | $210.47M↓ | $244.53M↑ | $193.58M↑ | $184.85M↑ | $159.62M |
Peer Comparison
JNJUNHPFE
Fundamentals
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced r...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.28B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
43.05%
Volume
Today's trading volume
2.52M
Recent News
Qualcomm upgrade, Intel initiation among today's top calls on Wall Street
Qualcomm upgrade, Intel initiation among today's top calls on Wall Street
Here Are Thursday’s Best Wall Street Analyst Research Calls: Brown-Forman, CoreWeave, Intel, JFrog, Keurig Dr. Pepper, Klarna Group, Qualcomm, Shift 4 Payments, and More
Pre-Market Stock Futures: Futures are trading higher this morning, after all the big funds and portfolio managers may have shown their hands on Wednesday, as the tech and chip stocks sell-off resumed after stocks started higher in the morning but faded in the afternoon. The tech sell-off came before Micron Technology (NASDAQ: MU) posted huge ... Here Are Thursday’s Best Wall Street Analyst Research Calls: Brown-Forman, CoreWeave, Intel, JFrog, Keurig Dr. Pepper, Klarna Group, Qualcomm, Shift 4 P
EXEL Down on Colorectal Cancer Study Data on Zanzalintinib
Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.
Exelixis CABINET Win Extends CABOMETYX Reach And Raises Valuation Questions
Exelixis (NasdaqGS:EXEL) reported pivotal phase 3 CABINET trial results for CABOMETYX in advanced neuroendocrine tumors at ASCO 2026. The trial showed a significant improvement in progression free survival compared with control treatment. Benefit was seen in both functional and non functional neuroendocrine tumor subgroups, and the study was stopped early due to superior efficacy. For investors tracking Exelixis, the new CABINET data adds fresh information around the company’s key oncology...
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.